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ABSTRACT
INTRODUCTION: Aerosol vaccination is a promising non-injectable method that provides immune re-
sistance to pathogens since it follows the natural route of transmission of many infectious agents. The im-
mune response, occurring after intranasal or respiratory vaccine administration, provides credible protec-
tion due to the common mucosal immune system, excellent blood supply, and lung permeability. 
AIM: The study aims to highlight the unconventional and perspective application use of aerosol dosage 
forms as a technological approach for vaccine drug delivery. 
MATERIALS AND METHODS: A detailed literature survey in scientific databases such as PubMed, Sci-
enceDirect, ResearchGate has been conducted, and the relevant information has been summarized and in-
terpreted. 
RESULTS: The aerosol vaccination method, as an alternative to the subcutaneous, intramuscular or intra-
dermal application route, ensures defense against the inhaled pathogens, avoiding at the same time draw-
backs associated with the injection administration such as the risk of reuse of disposable medical consum-
ables, potential spreading of blood-borne diseases and the necessity of qualified medical personnel. Addi-
tionally, aerosol vaccination is an easier and more practical approach for patients, leading to improved com-
pliance. Vaccines applied by the inhalation or nasal route of administration could be a successful approach 
for the treatment of diseases such as measles, tuberculosis, or influenza A, that although preventable, re-
main a global challenge.
CONCLUSION: The aerosol method is promising for vaccine delivery with the potential to be fully evalu-
ated in the upcoming years. 
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INTRODUCTION
Regular immunization remains the primary 
approach for the control and prevention of various 
diseases. The most often applied vaccines are admin-
istered by injection (intramuscular, subcutaneous, 
or intradermal) directly into the bloodstream pro-
viding high bioavailability of the active ingredients 
(e.g., antigens). By the injection method, a precise 
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dose can be easily ensured as well as a systemic im-
mune response (1). However, the application of sub-
cutaneous, intramuscular, and intradermal vaccines 
faces some challenges and drawbacks. For instance, 
parental vaccines lead to temporary local immunity. 
Whereas the active ingredients are widespread in the 
blood circulation, their concentration at the portal of 
entry, usually the mucosa of the respiratory and gas-
trointestinal tracts, is quite low (2).
Additionally, developing countries have low ac-
cess to vaccines due to the absence of medical per-
sonnel and insufficient vaccine import. Another lim-
itation associated with injection includes a potential 
risk of reuse of disposable needles or syringes, hence 
possible transmission of local and systemic infec-
tions such as AIDS and hepatitis (3). The parenter-
al administration of vaccines is also associated with 
inconvenience and pain that lead to a lack of compli-
ance especially by children (4). Last but not least, in-
jections carry many risks for the people by incorrect 
storage or application, such as local reaction (swell-
ing, bruising, inflammation, etc.) or toxic shock syn-
drome in case of non-sterile products or procedures 
(5). 
A promising alternative compared to the par-
enteral vaccination appear to be the nasal and inha-
lation routes. The aerosol application could provide 
a rapid immunization, primarily in the epidemic ar-
eas, where time-saving is a critical issue (6). The re-
spiratory and nasal vaccinations are proven to be saf-
er and more immunogenic in lower doses than injec-
tions. The nose and mouth are easily accessible, do 
not require the use of needles or syringes; therefore, 
the risk of infections is minimal (7). Aerosol vaccines 
can be applied easily by patients themselves, without 
the necessity of a hospital environment or causing 
stress to the patients (4,6).
Furthermore, the inhalation and nasal routes 
are reported as suitable for the administration of sev-
eral antigens at once (8,9). Aerosol vaccines show a 
better boosting response than subcutaneous ones. 
The outcomes from conducted studies indicate an 
increased resistance to virus exposure and more ex-
tended protection in infants of vaccinated mothers 
(10). The aerosol vaccination methods could be ap-
plied successfully in diseases such as measles, influ-
enza A, anthrax, and tuberculosis, whose elimina-
tion is still a priority nowadays (8,11,12,13).
Although numerous aerosol vaccine formu-
lations have been elaborated and studied in clini-
cal trials, their practical application remains a chal-
lenge. Some of the limitations associated with their 
widespread use include factors such as high expens-
es for materials and equipment, which increase the 
economic price of aerosol vaccines in general, tech-
nical difficulties in the formulation process, and po-
tential environmental issues (14). From a technologi-
cal aspect, strict control regarding particle size must 
be imposed to ensure drug penetration through the 
epithelium (15). In this context, the administration 
of the vaccine in the form of micro- and nanome-
ter-sized particles is characterized by increased effi-
ciency and drug delivery (16). From biopharmaceu-
tical point of view, factors such as the vital capacity 
of the lungs and airway condition should be consid-
ered since diseases like chronic obstructive pulmo-
nary disease severely hinder the penetration of drugs 
administered via aerosols into the respiratory sys-
tem; thus, leading to variations of dosages (17). With 
the need for consideration and optimization, aerosol 
vaccines are a promising and safe approach for mass 
immunization, an object of numerous clinical trials, 
whose potential is yet to be fully evaluated.
AIM
The study aims to summarize the relevant in-
formation about aerosol vaccines, to review their ad-
vantages and limitations, and to discuss their clini-
cal effectiveness.
MATERIALS AND METHODS
Comprehensive research in the scientific data-
bases PubMed, ScienceDirect, ResearchGate regard-
ing characteristics and potential use of inhaled and 
intranasal applied vaccines in the last twenty years 
has been conducted. 
Route of Immunity Introduction 
The point of entry of respiratory antigens plays 
a significant role in immunity due to the mucosal 
immune system (18,19). The latter consists of epithe-
lium and underlying connective tissue, impregnated 
with immune cells, nasal-associated lymphoid tissue, 
lymphoid tissue of the larynx and bronchi, and nu-
merous lymph nodes, dispersed along the respirato-
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ry tract (20). The epithelium contains four major im-
munocompetent cell types – macrophages, lympho-
cytes, dendritic, and M-cells (18,19). M- or MALT-
cells (mucosa-associated lymphoid tissue) are consid-
ered as the main reason for the occurrence of strong 
local respiratory immunity (18). 
Nasally applied vaccines mostly impact the lo-
cal protection of the organism, as opposed to the in-
halation route of administration, which is associated 
with systemic action. The epithelium of the respira-
tory tract is highly vascularized and covered in mi-
crovilli, which form a large absorption surface (5,16). 
Through the thin mucosa layer, especially in the al-
veoli, inhaled substances can penetrate the blood and 
lymph, where T-cells can contribute to a generalized 
immunity (20). Limitations associated with the in-
halation route include its unsuitability for asthmat-
ic patients due to possible inaccurate dosing since 
the penetration through the inflamed mucosa is not 
thoroughly studied, and dose administration addi-
tionally depends on the patient’s inhalation capabil-
ity (21,22). The use of nasally applied vaccines is not 
recommended to people with nerve disorders due to 
the single reported cases of facial paralysis associat-
ed with the application of intranasal influenza vac-
cine (17,18). 
However, in terms of being used as an alterna-
tive to injectable vaccines, aerosol vaccines are con-
sidered suitable since according to conducted trials, 
they show better tolerance and fewer side effects (Fig. 
1).
Specifics of Aerosol Dosage Forms
Depending on the delivery path – nasal or by 
inhalation, aerosol particle sizes should be taken into 
consideration, especially in the case of nebulized so-
lutions aiming to deliver small particles into the low-
er respiratory airways. According to the performed 
studies, ultrasound mesh nebulizers generating par-
ticles within 1 – 5 μm in diameter have been report-
ed to be the most efficient for deposition to the lower 
lungs (Table 1) (24). For 30 seconds, about 0.1 mL of 
vaccine can be delivered by aerosol, which is equiv-
alent to the antibody import provided by injection. 
Hence 5 mL are sufficient for the vaccination of 45 
children (25). Nanoparticles are also reported to be 
able to reach the peripheral lungs and significantly 
increase the permeability and reactivity of the im-
mune system to pathogens (18,24). Concerning the 
impact of size and size distribution for effective drug 
delivery, nasal sprays providing particles wider than 
5 μm are suited mainly to reach the upper respiratory 
mucosa. They are usually deposited at the orophar-
ynx due to ciliary action (18). 
Dry powders, suspensions, and solutions are re-
ported to be used as delivery systems for aerosol vac-
cination (13,18,25). Initially, solutions for nebuliza-
tion were studied as an aerosol vaccination alterna-
tive. Afterward, dry powders were investigated due to 
the advantages they offer. Since they do not contain 
a fluid phase needed for induction into the lungs and 
nose, they are characterized by an increased chemi-
cal and microbiological stability, without the neces-
sity of including preservatives (13,26). Dry powders 
are developed using spray-drying and freeze-drying 
techniques (27). In the formulation process, the co-
hesion between aerosol particles is an essential fac-
tor to be considered and prevented, usually by the 
addition of “carriers” such as lactose or leucine. By Fig. 1. Adverse reactions by route of vaccine administra-
tion (8)
Particle Size Lung Deposition
>5 μm Trapped in the upper airways
1-5 μm Deep lung deposition
<1 μm Diff usion through the pulmonary alveoli
500 nm Phagocytosis by alveolar macrophages
Table 1. Predicted aerosol deposition of different size par-
ticles in adult lungs (24)
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their inclusion to the compositions, the aggregation 
between small particles is overcome, and the size is 
kept in an optimal range during the formulation pro-
cess and during storage, facilitating drug deposition 
into the lungs (16,28). The in-process control of the 
dry powder inhalation dosage forms includes parti-
cle size analysis, size distribution, powder X-ray dif-
fraction, compatibility studies, and microscopic eval-
uation of the particle surface (29,30).
Therapeutic Impact of Aerosol Vaccines 
Different clinical studies have been conduct-
ed to evaluate the effectiveness of aerosol vaccines in 
case of diseases such as measles, tuberculosis, influ-
enza, anthrax, or Ebola virus disease (31-35).
Measles is an airborne infectious disease caused 
by a measles virus. The most distinctive symptom of 
this condition is the flat red rash densely spread over 
the face and body of the infected (31). Measles is re-
ported to be highly contagious, especially for non-
immune people. Although it is an avoidable disease, 
an object of numerous vaccination programs, it is 
still a massive cause of mortality, reaching an unrea-
sonable peak in 2015, manifested in 134 200 deaths 
worldwide (36). In 2002, the World Health Organi-
zation (WHO) founded a program named Measles 
Aerosol Project, which carried out clinical and non-
clinical studies to evaluate the potential of an aero-
sol vaccine against the disease. The outcomes from 
the conducted studies reported that the aerosol vac-
cine was safe, well-tolerated, and non-immunogenic 
(37). Similar results were obtained by various stud-
ies performed worldwide (8,25). Amor et al. car-
ried out a randomized trial on first-grade children 
in Mexico and reported that the tested aerosol vac-
cine was more immunogenic for measles antibodies 
and equally immunogenic for rubeola antibodies in 
comparison to a subcutaneous vaccine (8). Anoth-
er study among schoolchildren in Mexico also con-
firmed the superior immunogenicity of aerosol mea-
sles vaccine compared to a subcutaneous one man-
ifested with antibody level of 52-64% in the aerosol 
vaccinated group compared to 4-23% in the injection 
vaccine group (25). 
Tuberculosis is an infectious disease caused 
by Mycobacterium tuberculosis mainly affecting the 
lungs (38). Pulmonary tuberculosis is a cause of mil-
lions of deaths yearly, even though a reliable vaccine 
exists – Bacille Calmette-Guérin (BCG), established 
in the 1920s (12). When injected after birth, BCG 
protects against disseminated pediatric tuberculosis; 
however, protection in adults is reported to be vola-
tile (32). New strategies are elaborated, aiming to im-
prove the BCG effect using vectors as carriers for M. 
tuberculosis antigens (32). According to studies per-
formed on mice, the aerosol and nasal sprays showed 
better protection against M. tuberculosis than paren-
tal application (39). Results of a phase I clinical study, 
conducted in the UK, showed an improved efficacy, 
expressed in higher antibody levels reached by aero-
sol vaccination (using mesh nebulizers) compared to 
an intradermal one (40). 
Influenza is a significant cause of mortality for 
chronically diseased and immunosuppressed pa-
tients. Annually new parental vaccines are developed 
due to the continuously changing antigen variations. 
Limited induction of local immunity may be noted as 
their main drawback (2). Thereupon intranasal vac-
cines are a promising approach since they are report-
ed to increase local drug bioavailability to the mu-
cosa tissue (13). A study performed on rats investi-
gated the efficacy of the aerosol vaccine consisting of 
spray-dried influenza antigens and bio-lipids, exis-
tent in the pulmonary surfactant as excipients, com-
pared to the subcutaneous injections. The obtained 
results showed that the tested vaccines mainly induce 
the specific IFN-γ producing T cells and increase the 
synthesis of IL-2 in the spleen, ensuring increased ef-
ficiency due to developed immunity at the port of the 
entry (13). According to the outcomes from phase III 
clinical trials, improved effectiveness of intranasally 
applied influenza vaccine (Flumist) was reported in 
children compared to a conventional trivalent inacti-
vated vaccine (33).
Besides the diseases mentioned above, the po-
tential use of aerosol vaccines was also investigated 
regarding the Ebola virus disease and anthrax pre-
vention. In their study Meyer et al. tested on primates 
parainfluenza virus type 3 respiratory vaccine con-
taining glycoprotein of the Ebola virus, which in-
duced improved immunogenicity and specific T-cell 
response in the lungs compared to systemic replicon 
vaccine (35). Since the presence of anthrax spores re-
mains in the lungs after exposure, various studies in-
vestigate the effect of aerosol vaccines for the preven-
tion of the disease (41). In their research, Gaur et al. 
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reported the improved immunogenicity of intrana-
sally applied recombinant protective antigen-based 
anthrax vaccine in mice compared to subcutaneous 
ones (34). Regarding the formulation factors, great-
er effectiveness of the tested vaccine was determined 
when the protective antigen was intranasally applied 
in powder form than as a liquid (42).
Recent Advances in Aerosol Vaccines
Pathogens such as SARS-CoV, MERS-CoV, and 
SARS-CoV-2 have challenged scientists from all over 
the world in search of vaccines to treat virus-induced 
diseases. Although the first cluster of SARS cases oc-
curred in China’s Guangdong province in Novem-
ber 2002, there is still no specific treatment and ap-
proved vaccine. The earliest case of MERS dates back 
to April 2012, and to date, there is no approved vac-
cine or specific treatment, although the case fatality 
rate is 34.8%. The first cases of COVID-19 were re-
ported in Wuhan, China, in December 2019, and two 
months later, in February 2020, the World Health 
Organization (WHO) declared a pandemic (43). To-
day the confirmed cases of COVID-19 are about 
3.5 million in nearly 200 countries globally, and the 
number of infections and deaths will continue to rise 
(44). In the face of this gloomy outlook, researchers 
around the world have joined forces searching and 
identifying suitable treatments and vaccines to curb 
the pandemic (45). Several research teams considered 
the nasal route of administration as appropriate for 
COVID-19 vaccine candidates. The aim of research-
ers from the University of Waterloo in Canada is to 
deliver the DNA-based vaccine to cells in target tis-
sues and trigger the production of virus-like parti-
cles (VLP) that will induce an immune response (46). 
Furthermore, scientists from the University of East-
ern Finland are also developing a nasal COVID-19 
vaccine based on gene transfer technology (47). 
CoroFlu is a unique nasal vaccine against CO-
VID-19 that is built on a flu vaccine “backbone” (48). 
CoroFlu is under development by a collaboration be-
tween the University of Wisconsin-Madison and the 
US vaccine company FluGen and Hyderabad-based 
Bharat Biotech (49). 
AdCOVIDTM, a single-dose nasal vaccine in 
clinical trials, has the potential to stimulate multiple 
arms of the immune system. Altimmune Inc, in col-
laboration with the University of Birmingham, AL, 
US, utilizes its proprietary intranasal vaccine tech-
nology (NasoVAXTM, an influenza vaccine candi-
date based on the same platform technology; Phase 2 
clinical study) in the new AdCOVIDTM (50). 
Recently, APEPTICO Forschung und Ent-
wicklung GmbH, in collaboration with the Medi-
cal University Vienna, announced that Solnatide is 
into phase II placebo-controlled randomized study 
aiming to explore the efficacy of Solnatide IMP in 
SARS-CoV-2 positive patients with moderate-to-se-
vere ARDS and pulmonary permeability edema (51). 
Moreover, Neurimmune AG, Zurich, Switzer-
land, and Ethris GmbH, Munich, Germany, have 
partnered to develop an inhaled mRNA-encoded 
vaccine that combines Neurimmune’s human an-
tibody development based on high-throughput im-
munoglobulin sequence analyses from Covid-19 pa-
tients who have recovered from the disease and on 
Ethris’ pulmonary SNIM®RNA therapeutics plat-
form (49,52).
Aerosol vaccines, utilizing novel technologies 
in drug delivery, seem to be a promising approach in 
the prevention and treatment of the SARS-CoV-2 vi-
rus-induced diseases. 
CONCLUSION
Aerosol vaccines are a feasible alternative to 
conventional ones, characterized by their ability to 
provide local immunity, high patient compliance, 
safety profile, and according to the results from con-
ducted clinical trials - comparable or improved ef-
ficiency. Future aspects of aerosol vaccine develop-
ment include the necessity of further research to 
evaluate their full potential as well as technological 
and economic optimization of the formulation pro-
cess, which will further facilitate their widespread 
clinical use.
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